Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Sofinnova Investments
AddedFeb 13, 2024
UpdatedJun 28, 2026
Sofinnova Investments

Sofinnova Investments

Operating

Sofinnova, a Menlo Park-based private equity firm, specializes in IT, healthcare, and communications sectors.

Location
Menlo Park, CA, US
Founded
1974
Firm
Compare
Portfolio
Employees
Website

Investments

City Therapeutics
City Therapeutics
Series B

Total Raised

$234.5M

Rounds

2

Series B$99.5MJune 2026
OnCusp Therapeutics
OnCusp Therapeutics

Total Raised

$125M

Rounds

2

Series A$100MJanuary 2024
Aiolos Bio
Aiolos Bio
Acquired

Total Raised

$245M

Rounds

1

Series A$245MOctober 2023
Star Therapeutics
Star Therapeutics

Total Raised

$190M

Rounds

2

Series C$90MSeptember 2023
Rapport Therapeutics
Rapport Therapeutics

Total Raised

$250M

Rounds

2

Series B$150MAugust 2023
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals

Total Raised

$150.1M

Rounds

2

Series B$150MJune 2023
Quanta Therapeutics
Quanta Therapeutics

Total Raised

$140.7M

Rounds

4

Series D$50.7MMay 2023
Series C$60MOctober 2021
Series UnknownJanuary 2018
Antiva Biosciences
Antiva Biosciences

Total Raised

$140.3M

Rounds

9

Series E$53MApril 2023
Series D$31MNovember 2021
Series C$15MJuly 2018
XyloCor Therapeutics
XyloCor Therapeutics

Total Raised

$39.6M

Rounds

2

Series A$22.6MMarch 2021
Series A$17MDecember 2018
Atsena Therapeutics
Atsena Therapeutics

Total Raised

$87.6M

Rounds

3

Series A$55MDecember 2020
VelosBio
VelosBio
Acquired

Total Raised

$202.7M

Rounds

3

Series B$137MJuly 2020
Series A$58MOctober 2018
Bolt Biotherapeutics
Bolt Biotherapeutics
Public

Total Raised

$198.5M

Rounds

8

Series C$93.5MJuly 2020
Aeovian Pharmaceuticals
Aeovian Pharmaceuticals

Total Raised

$37.8M

Rounds

6

Series A$37MOctober 2019
NextCure
NextCure
Public

Total Raised

$310M

Rounds

5

Series B$93MNovember 2018
Rainier Therapeutics
Rainier Therapeutics

Total Raised

$89M

Rounds

5

Series B$20MMay 2018
Neurana Pharmaceuticals
Neurana Pharmaceuticals

Total Raised

$60M

Rounds

1

Series A$60MMay 2018
Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals
Public

Total Raised

$400M

Rounds

5

Series C$200MFebruary 2018
Pionyr Immunotherapeutics
Pionyr Immunotherapeutics

Total Raised

$352M

Rounds

4

Series B$62MDecember 2017
Medeor Therapeutics
Medeor Therapeutics

Total Raised

$75.8M

Rounds

2

Series B$57MNovember 2017